These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 12109640)
1. Aromatase inhibitors in breast cancer: current and evolving roles. Hill J; Moore H Cleve Clin J Med; 2002 Jul; 69(7):561-7. PubMed ID: 12109640 [TBL] [Abstract][Full Text] [Related]
2. Use of aromatase inhibitors in breast carcinoma. Santen RJ; Harvey HA Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791 [TBL] [Abstract][Full Text] [Related]
3. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. Roseman BJ; Buzdar AU; Singletary SE J Surg Oncol; 1997 Nov; 66(3):215-20. PubMed ID: 9369969 [TBL] [Abstract][Full Text] [Related]
4. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma]. Friedrichs K; Jänicke F Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325 [TBL] [Abstract][Full Text] [Related]
5. Emerging role of aromatase inhibitors in the treatment of breast cancer. Harvey HA Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789 [TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors in breast cancer: an update. Lake DE; Hudis C Cancer Control; 2002; 9(6):490-8. PubMed ID: 12514567 [TBL] [Abstract][Full Text] [Related]
7. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study]. Forciniti S Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205 [No Abstract] [Full Text] [Related]
8. Letrozole in breast cancer. Shahab N N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058 [No Abstract] [Full Text] [Related]
9. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer. Cunnick G; Mokbel K Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468 [TBL] [Abstract][Full Text] [Related]
10. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Goss PE; Strasser K Drugs; 2002; 62(6):957-66. PubMed ID: 11929341 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant aromatase inhibitors: are we there yet? Fleming GF Cancer; 2003 Nov; 98(9):1779-81. PubMed ID: 14584057 [No Abstract] [Full Text] [Related]
12. Aromatase inhibitor development and hormone therapy: a perspective. Brodie A Semin Oncol; 2003 Aug; 30(4 Suppl 14):12-22. PubMed ID: 14513433 [TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives. Santen RJ Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304 [TBL] [Abstract][Full Text] [Related]
14. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer? Hutchinson L Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795 [No Abstract] [Full Text] [Related]
15. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790 [TBL] [Abstract][Full Text] [Related]
16. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study]. Gori S; Anastasi P; Marrocolo F Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206 [No Abstract] [Full Text] [Related]
17. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer. Younus J; Vandenberg TA Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383 [TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Miller WR Semin Oncol; 2003 Aug; 30(4 Suppl 14):3-11. PubMed ID: 14513432 [TBL] [Abstract][Full Text] [Related]
20. New stars in the sky of treatment for early breast cancer. Piccart-Gebhart MJ N Engl J Med; 2004 Mar; 350(11):1140-2. PubMed ID: 15014188 [No Abstract] [Full Text] [Related] [Next] [New Search]